• 1
    National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington. DC: National Osteoporosis Foundation. 2010.
  • 2
    Vahle JL, Masahiko S, Long GG, Young JK, Francis PC, Englehardt JA, Westmore MS, Ma YL, Nold JB. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312.
  • 3
    Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1–84. in a 2-year study in Fischer 344 rats. Toxicol Pathol. 2006;34(7):92940.
  • 4
    Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, Gilbert L, Nanes MS, Zayzafoon M, Guldberg R, Lamar DL, Singer MA, Lane TF, Kronenberg HM, Weitzmann MN, Pacifici R. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009;10(3):22940.
  • 5
    Bellido T, Ali AA, Gubrij I, Potkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146(11):457783.
  • 6
    Rosen CJ. The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gen Expr. 2003;13(1):2538.
  • 7
    Krane SM. Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med. 2005;201(6):8413.
  • 8
    Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone. (1–34). J Clin Endocrinol Metab. 2004;89(7):33326.
  • 9
    Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008;6(1):2438.
  • 10
    Bradbeer JN, Arlot ME, Meunier PJ, Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol. 1992;37:2829.
  • 11
    Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1–34) therapy in women with severe osteoporosis. Bone. 2000;27(2):3118.
  • 12
    Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone. 1–84. Bone. 2009;44:139.
  • 13
    Hodsman AB, Steer BM, Fraher LJ, Drost DJ. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1–38) and salmon calcitonin in osteoporotic patients. Bone Miner. 1991;14:6783.
  • 14
    Reeve J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP. hPTH 1–34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporos Int. 1991;1:16270.
  • 15
    Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, Neer RM. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25-dihydroxyvitamin D. J Bone Miner Res. 1986;1:37781.
  • 16
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetić K, Müller R, Bilezikian JP, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:84653.
  • 17
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) (teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18:193241.
  • 18
    Hyldstrup L, Jorgensen JT, Gaich G. Assessment of effects of ly333334 [recombinant human parathyroid hormone (1–34)] on cortical bone using digital x-ray radiogrammetry. Bone. 2002;28:S97.
  • 19
    Uusi-Rasi K, Beck TJ, Oreskovic TL, Sato M, Bogado CE, Zanchetta JR. Teriparatide [rhPTH(1–34)] improves the structural geometry of the hip. J Bone Miner Res. 2002;17:S208.
  • 20
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–.
  • 21
    Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012;66(2):199209.
  • 22
    Murad MH, Drake MT, Mullan RJ, Mauch KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012 Jun; 97(6):187180.
  • 23
    Crandall CC, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report [Internet]. Comparative Effectiveness Review No. 53. AHRQ Publication No. 12-EHC023-EF Prepared by Southern California Evidence-based Practice Center—RAND Corporation, Santa Monica, CA, under Contract No. HHSA-290-2007-1006 2-I. Rockville, MD: Agency for Healthcare Research and Quality; 2012 Mar [cited 2012 Oct 18]. Available from.
  • 24
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):87882.
  • 25
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endrocrinol Metab. 2000;85(9):306976.
  • 26
    Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide (human parathyroid hormone (1–34)) therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):917.
  • 27
    Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporosis Int. 2005;16(5):5106.
  • 28
    Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):202839.
  • 29
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):334655.
  • 30
    Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. Efficacy and safety of human parathyroid hormone (1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003;88(11):521220.
  • 31
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med. 2007;146:32639.
  • 32
    Zanchetta JR, Bogado CE, Cisari C, Aslanidis S, Greisen H, Fox J, Lems W. Treatment of postmenopausal women with osteoporosis with PTH (1–84) for 36 months: treatment extension study. Curr Med Res Opin. 2010;26(11):262733.
  • 33
    Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005;90(3):15837.
  • 34
    McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley D, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165(15):17628.
  • 35
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21(11):178590.
  • 36
    Mazziotti G, Bilezikian JP, Canalis E, Cocchi D, Giustina A. New understanding and treatments for osteoporosis. Endocrine. 2012;41:5869.
  • 37
    Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1–34. vs calcitriol,calcium in the treatment of hypoparathyroidism. JAMA. 1996;276:6316.
  • 38
    Winer KK, Yanovski JA, Sarani B. Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone. 1–34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83:34806.
  • 39
    Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone (1–34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88:421420.
  • 40
    Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS. Cutler GB Jr. Synthetic human parathyroid hormone. 1–34. replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(2):3919.
  • 41
    Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. and the hypoparathyroid study group. The effect of adding PTH (1–84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26:235870.
  • 42
    Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21:192734.
  • 43
    Rubin MR, Dempster DW, Sliney J Jr, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP. PTH(1–84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26:272736.
  • 44
    Bilezikian JP, Mosekilde L, Shoback D, Vokes T, Mannstadt M, Clarke B, Lagast H, Garceau R. Efficacy of recombinant human parathyroid hormone (rhPTH[1–84]) for the treatment of adults with hypoparathyroidism: a randomized, double-blind, placebo-controlled study. Presented at The 94th Annual Meeting of The Endocrine Society;. 2012 June 23-26, Houston, TX.
  • 45
    Bilezikian J, Clarke BL, Mannstadt M, Vokes TJ, Shoback D, Lagast H, Garceau R. Effect of recombinant human parathyroid hormone (rhPTH[1–84]) on skeletal dynamics and BMD in hypoparathyroidism: the REPLACE study. Presented at the ASBMR Annual Meeting;. 2012 October 11-26; Minneapolis, MN, USA.
  • 46
    Cusano N, Rubin M, Ives R, Sliney J Jr, Bilezikian J. Treatment of hypoparathyroidism with PTH (1–84) is safe and effective for up to 4 years. Presented at the ASBMR Annual Meeting;. 2011 September 16-20; San Diego, CA, USA.
  • 47
    Cusano NE, Rubin MR, Sliney J Jr, Bilezikian JP. Mini-review: new therapeutic options in hypoparathyroidism. Endocrine. 2012;41:4104.
  • 48
    Ellegaard M, Jørgensen NR, Schwarz P. Parathyroid hormone and bone healing Calcif Tissue Int. 2010 Jul; 87(1):113.
  • 49
    Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):40414.
  • 50
    Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone. 1–84. accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011 Sep 7; 93(17):15837.
  • 51
    NIH ClinicalTrials gov identifier: NCT01473589. Effect of Teriparatide on Hip Fracture Healing [Internet]. Bethesda, MD: NIH; 2012 [cited. 2012 Oct 18]. Available from:
  • 52
    Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011 Sep; 96(9):267580.
  • 53
    Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1–34)]. J Oral Maxillofac Surg. 2007 Mar; 65(3):57380.
  • 54
    Lau AN, Adachi JD. Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1–34)] therapy. J Rheumatol. 2009 Aug; 36(8):18357.
  • 55
    Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004 Jul-Aug; 32(4):42638.
  • 56
    Tashjian AH, Goltzman D. Perspective on the interpretation of rat carcinogenicity studies for human PTH(1–34) and human PT. H(1–84). J Bone Miner Res. 2008 Jun; 23(6):80310.
  • 57
    Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009 Jul; 125(1):22934.
  • 58
    Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151.
  • 59
    Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from. 1973 to 2004: data from the Surveillance. Epidemiology, and End Results Program. Cancer. 2009; Apr; 115(7):153143.
  • 60
    U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Development of parathyroid hormone for the prevention and treatment of osteoporosis. Draft guidance. Rockville, MD: Center for Drug Evaluation and Research 2000 May 19 [cited. 2012 Oct 18]. Available from:
  • 61
    Watanabe A, Yoneyama S, Nakajima M, Sato N, Takao-Kawabata R, Isogai Y, Sakurai-Tanikawa A, Higuchi K, Shimoi A, Yamatoya H, Yoshida K, Kohira T. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1–34)). J Toxicol Sci. 2012;37(3):61729.
  • 62
    Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R. Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 2001 Feb; 28(2):1509.
  • 63
    Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L. Effect of treatment for 6 months with human parathyroid hormone (1–34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 1999 Sep; 25(3):3019.
  • 64
    Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1–34)]. J Bone Miner Res. 2008 Dec; 23(12):20339.
  • 65
    Turner CH, Burr DB, Hock JM, Brommage R, Sato M. The effects of PTH (1–34) on bone structure and strength in ovariectomized monkeys. In: Majumdar S, Bay BK, editors Non-invasive assessment of trabecular bone architecture and the competence of bone. New York: Plenum; pp 165180. 2001.
  • 66
    Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1–84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res. 2007 Feb; 22(2):26073.
  • 67
    Andrews E, Gilsenan A, Midkiff K, Sherril B, Wu Y, Mann B, Masica D. The US Postmarketing Surveillance Study of Adult Osteosarcoma Teriparatide study design findings from the first 7 years. JBMR. 2012 27.
  • 68
    Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide?. J Bone Miner Res. 2007 Feb; 22(2):334.
  • 69
    Subbiah V, Madsen VSS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010 Jun; 21(6):10415.
  • 70
    Lubitz R, Prasad S. Case report: osteosarcoma and teriparatide (abstract). Poster presented at the ASBMR 31st Annual Meeting. J Bone Miner Res. 2009; 24 (Suppl 1):SU0354.
  • 71
    Pietrogrande L. Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH(1–84) in the treatment of postmenopausal osteoporosis. Int J Womens Health. 2009;1:193203.
  • 72
    Tashjian AH Jr, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone. 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res. 2002 Jul; 17(7):115161.
  • 73
    Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF. Primary hyperparathyroidism and osteosarcoma; examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res. 2005;20:15628.
  • 74
    Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology. 1932;16:54758.
  • 75
    Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005 Aug; 26(5):688703.
  • 76
    Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM, Melton LJ 3rd. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med. 1998 Feb; 104(2):11522.
  • 77
    Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H. Pharmacokinetics of teriparatide (rhPTH[1–34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010 Dec; 87(6):48592.
  • 78
    Schwietert HR, Groen EW, Sollie FA, Jonkman JH. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1–84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther. 1997 Mar; 61(3):3606.
  • 79
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep; 349(13):121626.
  • 80
    Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr; 95(4):183845.
  • 81
    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007 Jan; 18(1):5968.
  • 82
    Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab. 2007 Sep; 92(9):353541.
  • 83
    Gold DT, Pantos BS, Masica DN, Misurski DA, Marcus R. Initial experience with teriparatide in the United States. Curr Med Res Opin. 2006 Apr; 22(4):7038.
  • 84
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25; 349(13):120715.
  • 85
    Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, Roschger P, Klaushofer K, Winer KK. PTH (1–34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. J Bone Miner Res. 2009;24:96473.
  • 86
    Adachi JD, Hanley DA, Lorraine JK, Yu M. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther. 2007;29:205569.
  • 87
    Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20:9438.
  • 88
    Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljnggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int. 2009;85:48493.
  • 89
    Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J. PTH (1–84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcif Tissue Int. 2008;83:8592.
  • 90
    Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int. 2006;17:16269.
  • 91
    Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009;20:62530.
  • 92
    Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA. Improved adherence with PTH (1–84) for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Osteoporosis Int. Epub. 2012 Aug 28.